Revenue
2019
2020
2021
2022
2023
2024
2025
Harmony Biosciences Holdings, Inc. (HRMY)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $868.5M | $714.7M | $582.0M | $437.9M | $305.4M | $159.7M | $6.0M |
| Gross profit | $670.1M | $557.9M | $460.8M | $354.4M | $249.9M | $132.0M | $4.4M |
| Research & development | $189.6M | $145.8M | $76.1M | $70.9M | $30.4M | $19.4M | $69.6M |
| Operating expenses | $461.6M | $367.1M | $268.8M | $234.2M | $162.4M | $115.0M | $150.3M |
| Operating income | $208.5M | $190.8M | $192.0M | $120.2M | $87.5M | $17.0M | −$145.9M |
| EBITDAderived | — | $214.9M | $216.4M | $143.6M | $106.4M | $27.2M | −$142.7M |
| Net income | $158.7M | $145.5M | $128.9M | $181.5M | $34.6M | −$36.9M | −$152.0M |
| Basic EPSper diluted share | $2.76 | $2.56 | $2.17 | $3.07 | $0.60 | -$2.48 | -$24.07 |
| Diluted EPSper diluted share | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | -$2.48 | -$24.07 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 26, 2026Form 4 · 10b5-1 | Kapadia SandipCHIEF FINANCIAL OFFICER | SellCommon Stock | 3.7K | $37.15 | $139.2K | 24.5K |
| Jan 15, 2026Form 4 · 10b5-1 | Kapadia SandipCHIEF FINANCIAL OFFICER | SellCommon Stock | 21.0K | $35.92 | $752.9K | 0 |
| Dec 12, 2025Form 4 · 10b5-1 | Dayno Jeffrey M.PRESIDENT, CEO | SellCommon Stock | 5.9K | $40.11 | $238.0K | 0 |
| Dec 12, 2025Form 4 · 10b5-1 | Dayno Jeffrey M.PRESIDENT, CEO | SellCommon Stock | 20.0K | $40.11 | $802.2K | 0 |
| Dec 5, 2025Form 4 · 10b5-1 | Kapadia SandipCHIEF FINANCIAL OFFICER | SellCommon Stock | 20.0K | $39.54 | $790.8K | 0 |